Cohen and Steers Inc (CNS)
Live price chart, market sentiment, and community perspectives for Cohen and Steers Inc (NYSE: CNS).
Live price chart, market sentiment, and community perspectives for Cohen and Steers Inc (NYSE: CNS).
On our desk, we are seeing solid momentum in Cohen and Steers as AUM approaches record levels at $101.1 billion. The four consecutive quarters of organic growth, highlighted by $1.3 billion in net inflows for Q2 2026, show that the rotation into the real estate sector is real. With a 3.5% dividend yield and a forward P/E trading at a discount to historical peaks, the setup looks compelling for income-focused allocators looking to diversify away from mega-cap tech.
Watching the valuation and long-term forecasts closely. While Q2 revenue came in higher at US$152.73 million with net income of US$49.34 million, some baseline fair value models suggest potential downside of around 13% from recent highs. Expense growth and persistent yield competition from 4%+ risk-free instruments remain tangible risks that could cap multiple expansion over the next several quarters.
From a balance sheet and operational perspective, the firm maintains low leverage and robust cash generation, which underpins the recent third-quarter dividend declaration of US$0.67 per share. REITs representing nearly half of AUM are benefiting from improved property fundamentals and double-digit year-to-date returns, but we must remain mindful of structural fee pressures and the lingering drag from alternative private real estate vehicles.
The appointment of Erik Schneberger as Executive Vice President and Chief Marketing Officer is an interesting strategic catalyst. CNS is clearly pushing to sharpen its global marketing and client engagement capabilities across channels and regions. If this leadership change successfully drives product positioning for their active ETFs—which have now crossed $1 billion in AUM—it could help offset some of the broader competitive pressures from alternative-asset managers.
Tracking the fundamental performance metrics, 86% of Cohen and Steers' AUM outperformed benchmarks over one year and an impressive 98% over three years. This consistency in outperformance is a strong retention tool, but investors must weigh these solid investment results against long-term consensus revenue projections pointing toward $611.2 million by 2029.
Explore plasma cleansing, somatic organ swaps, and BCI.